Neurosense Therapeutics Ltd Financials

No, Neurosense Therapeutics Ltd (NRSN) reported a net income of -$11.1M in fiscal year 2025.

Neurosense Therapeutics Ltd (NRSN) reported diluted earnings per share of $-0.44 for fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neurosense Therapeutics Ltd (NRSN) had EBITDA of -$11.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Neurosense Therapeutics Ltd (NRSN) generated -$7.7M in free cash flow during fiscal year 2025. This represents a 24.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Neurosense Therapeutics Ltd (NRSN) generated -$7.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Neurosense Therapeutics Ltd (NRSN) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Neurosense Therapeutics Ltd (NRSN) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Neurosense Therapeutics Ltd (NRSN) invested $6.2M in research and development during fiscal year 2025.

Neurosense Therapeutics Ltd (NRSN) had 33M shares outstanding as of fiscal year 2025.

Neurosense Therapeutics Ltd (NRSN) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Neurosense Therapeutics Ltd (NRSN) had a debt-to-equity ratio of -1.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Neurosense Therapeutics Ltd (NRSN) had a return on assets of -1082.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Neurosense Therapeutics Ltd (NRSN) had $166K in cash against an annual operating cash burn of $7.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Neurosense Therapeutics Ltd (NRSN) has negative shareholder equity of -$1.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Neurosense Therapeutics Ltd (NRSN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Neurosense Therapeutics Ltd (NRSN) has an earnings quality ratio of 0.69x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.